CALL/VERTEX PHARMACEUTICALS/700/0.1/21.06.24 | Market Closed - BOERSE MUENCHEN 19:25:30 28/05/2024 BST | ||
| 0.001 EUR | 0.00% |
|
| 1 month | -66.67% | ||
| 3 months | -96.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 0.001 | 0.00% |
| 27/05/24 | 0.001 | 0.00% |
| 24/05/24 | 0.001 | 0.00% |
| 23/05/24 | 0.001 | 0.00% |
| 22/05/24 | 0.001 | 0.00% |
Real-time BOERSE MUENCHEN
Last update May 28, 2024 at 07:25 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG19TD |
| ISIN | DE000GG19TD3 |
| Date issued | 18/12/2023 |
| Strike | 700 $ |
| Maturity | 21/06/2024 (24 Days) |
| Parity | 10 : 1 |
| Emission price | 0.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.117 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.499 € |
| Spread % | 99.80% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.57%
- Stock Market
- Warrants
- Warrant
